The Archive · 5 posts
Shield your health! 🛡️ Shield Therapeutics (STX) on the LSE advances treatments for iron deficiency with unique solutions. Discover more! 🌟
ACCRUFeR sales surge 54% as Shield hits positive EBIT, but $7.9M milestone flatters numbers. CFO exits, NY Medicaid risk awaits.
May 1, 2026
Showing 4 of 5 posts
Shield Therapeutics hits profitability in 2025 as ACCRUFeR dominates the US oral iron market. Record revenue and positive cash flow mark a turnaround.
JoshuaApril 10, 2026
Shield Therapeutics hits key cash flow milestone in Q4 2025 and targets operating profit in 2026, driven by strong ACCRUFeR growth.
JoshuaJanuary 21, 2026
Shield Therapeutics' ACCRUFeR® revenue soars 153% to $29.3m in 2024, driven by US growth and strategic global expansion into Canada, Asia & Europe. On track for cash flow positivity by 2025.
JoshuaApril 24, 2025
Shield Therapeutics signs exclusive Japan deal with VITAL-NET for ACCRUFeR®, securing $665k upfront, milestones & double-digit royalties in iron deficiency market.
JoshuaApril 22, 2025
Investing
April 24, 2025